



Small Animal Patients Needed for Clinical Studies – January 2021

The following clinical studies are recruiting patients at UW Veterinary Care. For more information, please visit our website or call Amanda Brooks, clinical research technician, at **608-890-3484**. Thank you for helping improve the health of animals.

- **Dermatology**
 - Dogs with **Recurrent Pyoderma** – evaluate efficacy of staphylococcal vaccine (currently on hold)
- **Dentistry**
 - Dogs with **Malignant Oral Tumors** – evaluate agreement between imaging and intraoperative techniques for identification of sentinel lymph nodes
- **General Surgery**
 - Dogs undergoing surgery for **Laryngeal Paralysis** – evaluate EMG and stimulation responsiveness
 - Dogs with **Mast Cell Tumors >2cm** – compare samples from punch biopsy to whole tumor specimen
- **Genetics**
 - Dogs (any breed) with **Laryngeal Paralysis** and pure-bred **Labrador Retrievers & Golden Retrievers** older than 11 years of age without Laryngeal Paralysis – investigate genetic heritability
 - **Labrador Retrievers & Rottweilers** with and without **Cruciate Disease** – investigate genetic heritability. Note: unaffected dogs over 8 years of age needed as controls
- **Internal Medicine**
 - Clinically healthy **Greyhounds** – investigate why Greyhounds have higher levels of homocysteine
 - Dogs with **Chronic Gastrointestinal Signs** – investigate necessity of fasting for the gastrointestinal panel
 - Dogs with **Documented Bladder Cancer (TCC)** – investigate environmental risk factors
- **Neurology**
 - Cats with **Seizures** – evaluate cause and effect of seizures on the brain in cats following euthanasia
 - Dogs with **Seizures** – evaluate cause and effect of seizures on the brain in dogs following euthanasia
- **Oncology**
 - Cats and Dogs **With and Without Cancer** – evaluate accuracy of canine scent detection to identify cancer
 - Cats with **Any Cancer** – evaluate palladia in combination with doxorubicin
 - Cats with **Any Cancer** – evaluate safety of meloxicam in combination with toceranib phosphate
 - Dogs with **Anal Sac Adenocarcinoma** – evaluate the effect of conformal hypofractionated radiotherapy
 - Dogs with **Any Malignant Tumor (except lymphoma or leukemia)** – evaluate a novel approach to stimulate the dog's own immune cells to fight against the dog's tumor
 - Dogs with **Any Malignant Tumor (except mast cell tumor or hemangiosarcoma)** – evaluate a novel anticancer drug that is administered orally
 - Dogs with **Documented Bladder Cancer (TCC)** – investigate environmental risk factors
 - Dogs with **Melanoma** – evaluate a combination of new immune therapy approaches with radiation therapy
 - Dogs with **Metastatic Melanoma** – evaluate an intravenous, targeted radiation treatment combined with an immunotherapy treatment
 - Dogs with **Nasal Tumors** – evaluate the effect of radiotherapy on oral health in dogs
 - Dogs with **Newly Diagnosed Lymphoma** – evaluate the addition of the first FDA-approved drug for canine lymphoma (Tanovea) to the standard-of-care chemotherapy protocol
 - Dogs with **Osteosarcoma** – evaluate the safety and anti-tumor/anti-pain effects of a novel treatment combination in dogs that have not been treated for this cancer with surgery, radiation therapy, or chemotherapy
 - Dogs **without Cancer, Ages 6-11** – may qualify for a 5-year study evaluating a vaccine against canine cancers
- **Ophthalmology**
 - Clinically healthy **Rabbits** – characterize retinal lesions in rabbits and determine the number of rabbits affected
 - **Siberian Huskies** 10+ years old or with a history of glaucoma – investigate genetic basis of glaucoma